What is Zacks Research's Forecast for TBPH Q3 Earnings?

Key Points

• Zacks Research predicts Theravance Biopharma will post earnings of (-$0.09) per share for Q3 2025, with a full-year estimate of (-$1.09) per share.
• Several analysts have upgraded Theravance Biopharma's stock to a "Strong Buy" rating, with a current consensus target price of $21.33.
• Insider Rhonda Farnum sold 10,000 shares at an average price of $11.39, reducing her stake by 2.97% to approximately $3.7 million in total ownership.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Stock analysts at Zacks Research issued their Q3 2025 earnings per share (EPS) estimates for Theravance Biopharma in a report issued on Tuesday, September 2nd. Zacks Research analyst Team forecasts that the biopharmaceutical company will post earnings of ($0.09) per share for the quarter. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.94 EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.17) EPS.

TBPH has been the subject of a number of other research reports. BTIG Research boosted their price target on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a research note on Tuesday, June 17th. Finally, Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Strong Buy" and a consensus price target of $21.33.

Theravance Biopharma Stock Up 0.4%

TBPH stock traded up $0.05 during trading on Friday, reaching $13.81. 101,476 shares of the company's stock were exchanged, compared to its average volume of 288,202. Theravance Biopharma has a 1-year low of $7.88 and a 1-year high of $14.55. The company's fifty day moving average price is $12.23 and its 200-day moving average price is $10.50. The firm has a market cap of $695.47 million, a PE ratio of 57.25 and a beta of 0.05.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in shares of Theravance Biopharma by 1,201.8% in the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 3,281 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 781 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Theravance Biopharma in the 1st quarter valued at approximately $101,000. R Squared Ltd lifted its position in shares of Theravance Biopharma by 636.6% in the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock valued at $112,000 after acquiring an additional 10,822 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $119,000. 99.10% of the stock is owned by institutional investors.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.90% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.